{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:03:04Z","timestamp":1791518584261,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40265-019-01074-4","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:39:10Z","timestamp":1551314350000},"page":"501-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Management of Post-transplant Hyperparathyroidism and Bone Disease"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-6925","authenticated-orcid":false,"given":"Rowena","family":"Delos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Maw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"issue":"5","key":"1074_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.ackd.2016.07.001","volume":"23","author":"JH Wang","year":"2016","unstructured":"Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016;23(5):281\u20136. https:\/\/doi.org\/10.1053\/j.ackd.2016.07.001 .","journal-title":"Adv Chronic Kidney Dis."},{"issue":"5","key":"1074_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ndt\/gfh128","volume":"19","author":"P Evenepoel","year":"2004","unstructured":"Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfh128 .","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/oxfordjournals.ndt.a027843","volume":"13","author":"W Reinhardt","year":"1998","unstructured":"Reinhardt W, Bartelworth H, Jockenhovel F, Schmidt-Gayk H, Witzke O, Wagner K, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13(2):436\u201342.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000110875","volume":"28","author":"SM Sprague","year":"2008","unstructured":"Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients\u2014a review. Am J Nephrol. 2008;28(2):246\u201353. https:\/\/doi.org\/10.1159\/000110875 .","journal-title":"Am J Nephrol"},{"issue":"1","key":"1074_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1399-0012.2010.01287.x","volume":"25","author":"JB Copley","year":"2011","unstructured":"Copley JB, Wuthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24\u201339. https:\/\/doi.org\/10.1111\/j.1399-0012.2010.01287.x .","journal-title":"Clin Transplant"},{"issue":"5","key":"1074_CR6","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1046\/j.1523-1755.1998.00142.x","volume":"54","author":"P Messa","year":"1998","unstructured":"Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 1998;54(5):1704\u201313. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00142.x .","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"1074_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/ndt\/13.suppl_3.94","volume":"13","author":"A Torres","year":"1998","unstructured":"Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13(Suppl 3):94\u20137.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/ctr.12291","volume":"28","author":"N Muirhead","year":"2014","unstructured":"Muirhead N, Zaltman JS, Gill JS, Churchill DN, Poulin-Costello M, Mann V, et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transplant. 2014;28(2):161\u20135. https:\/\/doi.org\/10.1111\/ctr.12291 .","journal-title":"Clin Transplant"},{"issue":"7","key":"1074_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1373\/clinchem.2003.030759","volume":"50","author":"SA Santini","year":"2004","unstructured":"Santini SA, Carrozza C, Vulpio C, Capoluongo E, Luciani G, Lulli P, et al. Assessment of parathyroid function in clinical practice: which parathyroid hormone assay is better? Clin Chem. 2004;50(7):1247\u201350. https:\/\/doi.org\/10.1373\/clinchem.2003.030759 .","journal-title":"Clin Chem"},{"issue":"12","key":"1074_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u20138. https:\/\/doi.org\/10.1038\/ki.2011.47 .","journal-title":"Kidney Int"},{"issue":"1","key":"1074_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/TP.0000000000000823","volume":"100","author":"M Wolf","year":"2016","unstructured":"Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, et al. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation. 2016;100(1):184\u201393. https:\/\/doi.org\/10.1097\/tp.0000000000000823 .","journal-title":"Transplantation"},{"issue":"3","key":"1074_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1525-139X.2006.00161.x","volume":"19","author":"E Lewin","year":"2006","unstructured":"Lewin E, Huan J, Olgaard K. Parathyroid growth and suppression in renal failure. Semin Dial. 2006;19(3):238\u201345. https:\/\/doi.org\/10.1111\/j.1525-139X.2006.00161.x .","journal-title":"Semin Dial"},{"issue":"7","key":"1074_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2215\/CJN.11371015","volume":"11","author":"A Bouquegneau","year":"2016","unstructured":"Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282\u201396. https:\/\/doi.org\/10.2215\/cjn.11371015 .","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"1074_CR14","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/ajt.12425","volume":"13","author":"P Perrin","year":"2013","unstructured":"Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653\u201363. https:\/\/doi.org\/10.1111\/ajt.12425 .","journal-title":"Am J Transplant."},{"issue":"2","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/TP.0000000000000583","volume":"99","author":"H Pihlstrom","year":"2015","unstructured":"Pihlstrom H, Dahle DO, Mjoen G, Pilz S, Marz W, Abedini S, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015;99(2):351\u20139. https:\/\/doi.org\/10.1097\/tp.0000000000000583 .","journal-title":"Transplantation"},{"issue":"11","key":"1074_CR16","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/ajt.12913","volume":"14","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Delos Santos R. Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia. Am J Transplant. 2014;14(11):2446\u20137. https:\/\/doi.org\/10.1111\/ajt.12913 .","journal-title":"Am J Transplant."},{"issue":"1","key":"1074_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92(1):26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006 .","journal-title":"Kidney Int"},{"issue":"6","key":"1074_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737\u201351. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.019 .","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1074_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12882-018-1037-8","volume":"19","author":"JO Burton","year":"2018","unstructured":"Burton JO, Goldsmith DJ, Ruddock N, Shroff R, Wan M. Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. BMC Nephrol. 2018;19(1):240. https:\/\/doi.org\/10.1186\/s12882-018-1037-8 .","journal-title":"BMC Nephrol."},{"key":"1074_CR20","unstructured":"NICE. National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance TA117. 2007. Retrieved from https:\/\/www.nice.org.uk\/guidance\/ta117 ."},{"issue":"3","key":"1074_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apheresis Dial. 2013;17(3):247\u201388. https:\/\/doi.org\/10.1111\/1744-9987.12058 .","journal-title":"Ther Apheresis Dial."},{"key":"1074_CR22","unstructured":"CARI. Caring for Australasians with Renal Impairment. KHA-CARI adaptation of the KDIGO guideline for the care of kidney transplant recipients. 2012. Retrieved from http:\/\/www.cari.org.au\/Transplantation\/transplantation%20care%20of%20recipients\/transplant_care_of_recipients.html ."},{"issue":"2","key":"1074_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1523-1755.2004.00432.x","volume":"65","author":"A Torres","year":"2004","unstructured":"Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65(2):705\u201312. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00432.x .","journal-title":"Kidney Int"},{"issue":"1","key":"1074_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1210\/jcem-52-1-111","volume":"52","author":"TJ Hahn","year":"1981","unstructured":"Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52(1):111\u20135. https:\/\/doi.org\/10.1210\/jcem-52-1-111 .","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"1074_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.beem.2011.05.008","volume":"25","author":"L Lieben","year":"2011","unstructured":"Lieben L, Carmeliet G, Masuyama R. Calcemic actions of vitamin D: effects on the intestine, kidney and bone. Best Pract Res Clin Endocrinol Metab. 2011;25(4):561\u201372. https:\/\/doi.org\/10.1016\/j.beem.2011.05.008 .","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"1074_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/01.TP.0000149322.70295.A5","volume":"79","author":"KM Wissing","year":"2005","unstructured":"Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation. 2005;79(1):108\u201315.","journal-title":"Transplantation"},{"issue":"6","key":"1074_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ajt.12227","volume":"13","author":"H Amer","year":"2013","unstructured":"Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13(6):1576\u201385. https:\/\/doi.org\/10.1111\/ajt.12227 .","journal-title":"Am J Transplant."},{"issue":"5","key":"1074_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.2013111185","volume":"26","author":"M Trillini","year":"2015","unstructured":"Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26(5):1205\u201314. https:\/\/doi.org\/10.1681\/asn.2013111185 .","journal-title":"J Am Soc Nephrol."},{"issue":"9752","key":"1074_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D Zeeuw de","year":"2010","unstructured":"de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(10)61032-x .","journal-title":"Lancet"},{"issue":"1","key":"1074_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ekir.2017.08.016","volume":"3","author":"JM Cruzado","year":"2018","unstructured":"Cruzado JM, Lauzurica R, Pascual J, Marcen R, Moreso F, Gutierrez-Dalmau A, et al. Paricalcitol versus calcifediol for treating hyperparathyroidism in kidney transplant recipients. Kidney Int Rep. 2018;3(1):122\u201332. https:\/\/doi.org\/10.1016\/j.ekir.2017.08.016 .","journal-title":"Kidney Int Rep."},{"issue":"9","key":"1074_CR31","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1093\/ndt\/gfl201","volume":"21","author":"NC Boudville","year":"2006","unstructured":"Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006;21(9):2621\u20134. https:\/\/doi.org\/10.1093\/ndt\/gfl201 .","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR32","doi-asserted-by":"publisher","first-page":"F253","DOI":"10.1152\/ajprenal.00302.2004","volume":"288","author":"M Rodriguez","year":"2005","unstructured":"Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288(2):F253\u201364. https:\/\/doi.org\/10.1152\/ajprenal.00302.2004 .","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1074_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.trre.2010.01.001","volume":"24","author":"E Morales","year":"2010","unstructured":"Morales E, Gutierrez E, Andres A. Treatment with calcimimetics in kidney transplantation. Transplant Revi (Orlando, Fla). 2010;24(2):79\u201388. https:\/\/doi.org\/10.1016\/j.trre.2010.01.001 .","journal-title":"Transplant Revi (Orlando, Fla)."},{"issue":"15","key":"1074_CR34","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa031633 .","journal-title":"N Engl J Med."},{"issue":"6","key":"1074_CR35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/ndt\/gfk018","volume":"21","author":"N Leonard","year":"2006","unstructured":"Leonard N, Brown JH. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet. Nephrol Dial Transplant. 2006;21(6):1736. https:\/\/doi.org\/10.1093\/ndt\/gfk018 .","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/ndt\/gfl560","volume":"22","author":"AL Serra","year":"2007","unstructured":"Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22(2):577\u201383. https:\/\/doi.org\/10.1093\/ndt\/gfl560 .","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"1074_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/TP.0b013e3182079431","volume":"91","author":"A Schwarz","year":"2011","unstructured":"Schwarz A, Merkel S, Leitolf H, Haller H. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation. 2011;91(5):560\u20135. https:\/\/doi.org\/10.1097\/TP.0b013e3182079431 .","journal-title":"Transplantation"},{"issue":"11","key":"1074_CR38","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1111\/ajt.12911","volume":"14","author":"P Evenepoel","year":"2014","unstructured":"Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014;14(11):2545\u201355.","journal-title":"Am J Transplant"},{"issue":"3","key":"1074_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.6002\/ect.2016.0342","volume":"16","author":"V Zavvos","year":"2018","unstructured":"Zavvos V, Fyssa L, Papasotiriou M, Papachristou E, Ntrinias T, Savvidaki E, et al. Long-term use of cinacalcet in kidney transplant recipients with hypercalcemic secondary hyperparathyroidism: a single-center prospective study. Exp Clin Transplant. 2018;16(3):287\u201393. https:\/\/doi.org\/10.6002\/ect.2016.0342 .","journal-title":"Exp Clin Transplant."},{"issue":"4","key":"1074_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000337526","volume":"35","author":"M Courbebaisse","year":"2012","unstructured":"Courbebaisse M, Diet C, Timsit MO, Mamzer MF, Thervet E, Noel LH, et al. Effects of cinacalcet in renal transplant patients with hyperparathyroidism. Am J Nephrol. 2012;35(4):341\u20138. https:\/\/doi.org\/10.1159\/000337526 .","journal-title":"Am J Nephrol"},{"issue":"3","key":"1074_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1399-0012.2011.01524.x","volume":"26","author":"P Evenepoel","year":"2012","unstructured":"Evenepoel P, Sprangers B, Lerut E, Bammens B, Claes K, Kuypers D, et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transplant. 2012;26(3):393\u2013402. https:\/\/doi.org\/10.1111\/j.1399-0012.2011.01524.x .","journal-title":"Clin Transplant"},{"issue":"8","key":"1074_CR42","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1093\/ndt\/gfm270","volume":"22","author":"AE Kruse","year":"2007","unstructured":"Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2007;22(8):2362\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfm270 .","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1074_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364. https:\/\/doi.org\/10.1001\/jama.2016.19468 .","journal-title":"JAMA"},{"issue":"7","key":"1074_CR44","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","volume":"20","author":"AE Kruse","year":"2005","unstructured":"Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1311\u20134. https:\/\/doi.org\/10.1093\/ndt\/gfh924 .","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"1074_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1159\/000304180","volume":"31","author":"KA Borchhardt","year":"2010","unstructured":"Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010;31(6):482\u20139. https:\/\/doi.org\/10.1159\/000304180 .","journal-title":"Am J Nephrol"},{"issue":"4","key":"1074_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CNP69269","volume":"69","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008;69(4):269\u201378.","journal-title":"Clin Nephrol."},{"issue":"7","key":"1074_CR47","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1681\/ASN.V1271530","volume":"12","author":"W Grotz","year":"2001","unstructured":"Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530\u20137.","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"1074_CR48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1046\/j.1523-1755.2003.00816.x","volume":"63","author":"M Haas","year":"2003","unstructured":"Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6\u00a0months after renal transplantation. Kidney Int. 2003;63(3):1130\u20136. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00816.x .","journal-title":"Kidney Int"},{"issue":"2","key":"1074_CR49","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1046\/j.1523-1755.2000.00890.x","volume":"57","author":"SL Fan","year":"2000","unstructured":"Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;57(2):684\u201390. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00890.x .","journal-title":"Kidney Int"},{"issue":"2","key":"1074_CR50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.transproceed.2011.01.025","volume":"43","author":"S Abediazar","year":"2011","unstructured":"Abediazar S, Nakhjavani MR. Effect of alendronate on early bone loss of renal transplant recipients. Transplant Proc. 2011;43(2):565\u20137. https:\/\/doi.org\/10.1016\/j.transproceed.2011.01.025 .","journal-title":"Transplant Proc."},{"issue":"8","key":"1074_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1432-2277.2007.00501.x","volume":"20","author":"JV Torregrosa","year":"2007","unstructured":"Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubi S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transplant Int. 2007;20(8):708\u201311. https:\/\/doi.org\/10.1111\/j.1432-2277.2007.00501.x .","journal-title":"Transplant Int."},{"issue":"2","key":"1074_CR52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/TP.0b013e318176b40f","volume":"86","author":"E Conley","year":"2008","unstructured":"Conley E, Muth B, Samaniego M, Lotfi M, Voss B, Armbrust M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation. 2008;86(2):231\u20137. https:\/\/doi.org\/10.1097\/TP.0b013e318176b40f .","journal-title":"Transplantation"},{"issue":"8","key":"1074_CR53","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/00007890-199810270-00007","volume":"66","author":"WH Grotz","year":"1998","unstructured":"Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation. 1998;66(8):1004\u20138.","journal-title":"Transplantation"},{"issue":"4","key":"1074_CR54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2004.12.007","volume":"45","author":"SC Palmer","year":"2005","unstructured":"Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638\u201349.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1074_CR55","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/ctr.12792","volume":"30","author":"SM Toth-Manikowski","year":"2016","unstructured":"Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2016;30(9):1090\u20136. https:\/\/doi.org\/10.1111\/ctr.12792 .","journal-title":"Clin Transplant"},{"issue":"2","key":"1074_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/tri.12691","volume":"29","author":"EB Versele","year":"2016","unstructured":"Versele EB, Van Laecke S, Dhondt AW, Verbeke F, Vanholder R, Van Biesen W, et al. Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplant Int. 2016;29(2):153\u201364. https:\/\/doi.org\/10.1111\/tri.12691 .","journal-title":"Transplant Int."},{"issue":"3","key":"1074_CR57","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rdc.2011.07.004","volume":"37","author":"RK Dore","year":"2011","unstructured":"Dore RK. The RANKL pathway and denosumab. Rheum Dis Clin N Am. 2011;37(3):433\u201352. https:\/\/doi.org\/10.1016\/j.rdc.2011.07.004 .","journal-title":"Rheum Dis Clin N Am."},{"issue":"8","key":"1074_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493 .","journal-title":"N Engl J Med."},{"issue":"8","key":"1074_CR59","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Mineral Res. 2011;26(8):1829\u201335. https:\/\/doi.org\/10.1002\/jbmr.403 .","journal-title":"J Bone Mineral Res."},{"issue":"6","key":"1074_CR60","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/ajt.13692","volume":"16","author":"M Bonani","year":"2016","unstructured":"Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882\u201391. https:\/\/doi.org\/10.1111\/ajt.13692 .","journal-title":"Am J Transplant."},{"issue":"5","key":"1074_CR61","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1159\/000447930","volume":"41","author":"M Bonani","year":"2016","unstructured":"Bonani M, Meyer U, Frey D, Graf N, Bischoff-Ferrari HA, Wuthrich RP. Effect of denosumab on peripheral compartmental bone density, microarchitecture and estimated bone strength in de novo kidney transplant recipients. Kidney Blood Press Res. 2016;41(5):614\u201322. https:\/\/doi.org\/10.1159\/000447930 .","journal-title":"Kidney Blood Press Res."},{"issue":"9","key":"1074_CR62","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1097\/TP.0000000000001547","volume":"101","author":"M Bonani","year":"2017","unstructured":"Bonani M, Frey D, de Rougemont O, Mueller NJ, Mueller TF, Graf N, et al. Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation. 2017;101(9):2139\u201345. https:\/\/doi.org\/10.1097\/tp.0000000000001547 .","journal-title":"Transplantation"},{"key":"1074_CR63","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fendo.2018.00162","volume":"9","author":"J Brunova","year":"2018","unstructured":"Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol. 2018;9:162. https:\/\/doi.org\/10.3389\/fendo.2018.00162 .","journal-title":"Front Endocrinol."},{"issue":"1","key":"1074_CR64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/ckj\/sfs158","volume":"6","author":"JV Torregrosa","year":"2013","unstructured":"Torregrosa JV. Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient. Clin Kidney J. 2013;6(1):122. https:\/\/doi.org\/10.1093\/ckj\/sfs158 .","journal-title":"Clin Kidney J."},{"issue":"4","key":"1074_CR65","doi-asserted-by":"publisher","first-page":"756-e1","DOI":"10.1016\/j.ajem.2012.11.011","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med. 2013;31(4):756-e1. https:\/\/doi.org\/10.1016\/j.ajem.2012.11.011 .","journal-title":"Am J Emerg Med."},{"issue":"11","key":"1074_CR66","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y. Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Internal Med J. 2013;43(11):1243\u20136. https:\/\/doi.org\/10.1111\/imj.12283 .","journal-title":"Internal Med J."},{"issue":"2","key":"1074_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ckj\/sft014","volume":"6","author":"P Ivanov","year":"2013","unstructured":"Ivanov P, Khedr M. Prolonged hypocalcaemia following a single dose of 60\u00a0mg denosumab in two patients with CKD 4\/5 on cinacalcet treatment for tertiary hyperparathyroidism. Clin Kid J. 2013;6(2):245. https:\/\/doi.org\/10.1093\/ckj\/sft014 .","journal-title":"Clin Kid J."},{"issue":"9","key":"1074_CR68","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8(9):1864\u201370. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02327.x .","journal-title":"Am J Transplant."},{"issue":"9","key":"1074_CR69","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","volume":"166","author":"LM Wilson","year":"2017","unstructured":"Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2017;166(9):649\u201358. https:\/\/doi.org\/10.7326\/m16-2752 .","journal-title":"Ann Intern Med"},{"issue":"6","key":"1074_CR70","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/ndt\/gfm044","volume":"22","author":"P Evenepoel","year":"2007","unstructured":"Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant. 2007;22(6):1730\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfm044 .","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"1074_CR71","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00423-015-1344-5","volume":"400","author":"K Lorenz","year":"2015","unstructured":"Lorenz K, Bartsch DK, Sancho JJ, Guigard S, Triponez F. Surgical management of secondary hyperparathyroidism in chronic kidney disease\u2014a consensus report of the European Society of Endocrine Surgeons. Langenbeck\u2019s Arch Surg. 2015;400(8):907\u201327. https:\/\/doi.org\/10.1007\/s00423-015-1344-5 .","journal-title":"Langenbeck\u2019s Arch Surg."},{"issue":"1","key":"1074_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/TP.0b013e3182530699","volume":"94","author":"RL Yang","year":"2012","unstructured":"Yang RL, Freeman K, Reinke CE, Fraker DL, Karakousis GC, Kelz RR, et al. Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. Transplantation. 2012;94(1):70\u20136. https:\/\/doi.org\/10.1097\/TP.0b013e3182530699 .","journal-title":"Transplantation"},{"issue":"8","key":"1074_CR73","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1681\/ASN.2015060622","volume":"27","author":"JM Cruzado","year":"2016","unstructured":"Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gomez-Vaquero C, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27(8):2487\u201394. https:\/\/doi.org\/10.1681\/asn.2015060622 .","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"1074_CR74","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/ndt\/gfv334","volume":"30","author":"KM Ivarsson","year":"2015","unstructured":"Ivarsson KM, Akaberi S, Isaksson E, Reihner E, Rylance R, Prutz KG, et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dialy Transplant. 2015;30(12):2027\u201333. https:\/\/doi.org\/10.1093\/ndt\/gfv334 .","journal-title":"Nephrol Dialy Transplant."},{"issue":"2","key":"1074_CR75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88(2):350\u20139. https:\/\/doi.org\/10.1038\/ki.2015.72 .","journal-title":"Kidney Int"},{"issue":"4","key":"1074_CR76","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jamcollsurg.2011.12.046","volume":"214","author":"J Sharma","year":"2012","unstructured":"Sharma J, Raggi P, Kutner N, Bailey J, Zhang R, Huang Y, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am College Surg. 2012;214(4):400\u20137. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2011.12.046 (discussion 7-8).","journal-title":"J Am College Surg."},{"issue":"5","key":"1074_CR77","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/nep.12801","volume":"22","author":"J Chen","year":"2017","unstructured":"Chen J, Jia X, Kong X, Wang Z, Cui M, Xu D. Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: a systematic review and meta-analysis. Nephrology (Carlton, Vic). 2017;22(5):388\u201396. https:\/\/doi.org\/10.1111\/nep.12801 .","journal-title":"Nephrology (Carlton, Vic)."},{"issue":"6","key":"1074_CR78","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/BF01665309","volume":"15","author":"M Rothmund","year":"1991","unstructured":"Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15(6):745\u201350.","journal-title":"World J Surg"},{"issue":"6","key":"1074_CR79","first-page":"382","volume":"41","author":"ML Nicholson","year":"1996","unstructured":"Nicholson ML, Veitch PS, Feehally J. Parathyroidectomy in chronic renal failure: comparison of three operative strategies. J R Coll Surg Edinb. 1996;41(6):382\u20137.","journal-title":"J R Coll Surg Edinb"},{"issue":"1","key":"1074_CR80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.surg.2018.04.076","volume":"165","author":"E Isaksson","year":"2019","unstructured":"Isaksson E, Ivarsson K, Akaberi S, Muth A, Prutz KG, Clyne N, et al. Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery. 2019;165(1):142\u201350. https:\/\/doi.org\/10.1016\/j.surg.2018.04.076 .","journal-title":"Surgery."},{"issue":"6","key":"1074_CR81","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00423-006-0070-4","volume":"391","author":"F Triponez","year":"2006","unstructured":"Triponez F, Dosseh D, Hazzan M, Noel C, Soudan B, Lokey J, et al. Accuracy of intra-operative PTH measurement during subtotal parathyroidectomy for tertiary hyperparathyroidism after renal transplantation. Langenbeck\u2019s Arch Surg. 2006;391(6):561\u20135. https:\/\/doi.org\/10.1007\/s00423-006-0070-4 .","journal-title":"Langenbeck\u2019s Arch Surg."},{"issue":"4","key":"1074_CR82","doi-asserted-by":"publisher","first-page":"494","DOI":"10.5935\/1808-8694.20130088","volume":"79","author":"MN Ohe","year":"2013","unstructured":"Ohe MN, Santos RO, Kunii IS, Carvalho AB, Abrahao M, Neves MC, et al. Intraoperative PTH cutoff definition to predict successful parathyroidectomy in secondary and tertiary hyperparathyroidism. Braz J Otorhinolaryngol. 2013;79(4):494\u20139. https:\/\/doi.org\/10.5935\/1808-8694.20130088 .","journal-title":"Braz J Otorhinolaryngol."},{"issue":"2","key":"1074_CR83","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jss.2006.11.025","volume":"141","author":"Y Ikeda","year":"2007","unstructured":"Ikeda Y, Kurihara H, Morita N, Miyabe R, Takami H. The role of quick bio-intact PTH(1\u201384) assay during parathyroidectomy for secondary hyperparathyroidism. J Surg Res. 2007;141(2):306\u201310. https:\/\/doi.org\/10.1016\/j.jss.2006.11.025 .","journal-title":"J Surg Res."},{"issue":"6","key":"1074_CR84","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1373\/clinchem.2005.065490","volume":"52","author":"C Bieglmayer","year":"2006","unstructured":"Bieglmayer C, Kaczirek K, Prager G, Niederle B. Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. Clin Chem. 2006;52(6):1112\u20139. https:\/\/doi.org\/10.1373\/clinchem.2005.065490 .","journal-title":"Clin Chem"},{"issue":"10","key":"1074_CR85","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/hed.21328","volume":"32","author":"K Freriks","year":"2010","unstructured":"Freriks K, Hermus AR, de Sevaux RG, Bonenkamp HJ, Biert J, den Heijer M, et al. Usefulness of intraoperative parathyroid hormone measurements in patients with renal hyperparathyroidism. Head Neck. 2010;32(10):1328\u201335. https:\/\/doi.org\/10.1002\/hed.21328 .","journal-title":"Head Neck"},{"issue":"7\u20138","key":"1074_CR86","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.clinbiochem.2016.01.012","volume":"49","author":"C Vulpio","year":"2016","unstructured":"Vulpio C, Bossola M, Di Stasio E, Pepe G, Nure E, Magalini S, et al. Intra-operative parathyroid hormone monitoring through central laboratory is accurate in renal secondary hyperparathyroidism. Clin Biochem. 2016;49(7\u20138):538\u201343. https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.01.012 .","journal-title":"Clin Biochem"},{"issue":"6","key":"1074_CR87","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/cjn.10390917","volume":"13","author":"WL Lau","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952\u201361. https:\/\/doi.org\/10.2215\/cjn.10390917 .","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"1074_CR88","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s002689900524","volume":"22","author":"M Numano","year":"1998","unstructured":"Numano M, Tominaga Y, Uchida K, Orihara A, Tanaka Y, Takagi H. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg. 1998;22(10):1098\u2013102 (discussion 103).","journal-title":"World J Surg."},{"issue":"2","key":"1074_CR89","first-page":"120","volume":"59","author":"WB Carter","year":"1993","unstructured":"Carter WB, Carter DL, Cohn HE. Cause and current management of reoperative hyperparathyroidism. Am Surg. 1993;59(2):120\u20134.","journal-title":"Am Surg."},{"issue":"3","key":"1074_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00268-005-0279-3","volume":"30","author":"TH Pham","year":"2006","unstructured":"Pham TH, Sterioff S, Mullan BP, Wiseman GA, Sebo TJ, Grant CS. Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism. World J Surg. 2006;30(3):327\u201332. https:\/\/doi.org\/10.1007\/s00268-005-0279-3 .","journal-title":"World J Surg"},{"issue":"1","key":"1074_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00423-007-0151-z","volume":"393","author":"A Rosa de la","year":"2008","unstructured":"de la Rosa A, Jimeno J, Membrilla E, Sancho JJ, Pereira JA, Sitges-Serra A. Usefulness of preoperative Tc-mibi parathyroid scintigraphy in secondary hyperparathyroidism. Langenbeck\u2019s Arch Surg. 2008;393(1):21\u20134. https:\/\/doi.org\/10.1007\/s00423-007-0151-z .","journal-title":"Langenbeck\u2019s Arch Surg."},{"issue":"6","key":"1074_CR92","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/SLA.0b013e3181b0c7f4","volume":"250","author":"G Gasparri","year":"2009","unstructured":"Gasparri G, Camandona M, Bertoldo U, Sargiotto A, Papotti M, Raggio E, et al. The usefulness of preoperative dual-phase 99mTc MIBI-scintigraphy and IO-PTH assay in the treatment of secondary and tertiary hyperparathyroidism. Ann Surg. 2009;250(6):868\u201371. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b0c7f4 .","journal-title":"Ann Surg"},{"issue":"3","key":"1074_CR93","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00268-014-2878-3","volume":"39","author":"E Alkhalili","year":"2015","unstructured":"Alkhalili E, Tasci Y, Aksoy E, Aliyev S, Soundararajan S, Taskin E, et al. The utility of neck ultrasound and sestamibi scans in patients with secondary and tertiary hyperparathyroidism. World J Surg. 2015;39(3):701\u20135. https:\/\/doi.org\/10.1007\/s00268-014-2878-3 .","journal-title":"World J Surg"},{"issue":"1","key":"1074_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.03520414","volume":"10","author":"A Ishani","year":"2015","unstructured":"Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10(1):90\u20137. https:\/\/doi.org\/10.2215\/cjn.03520414 .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1074_CR95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/000313480407000204","volume":"70","author":"EA Mittendorf","year":"2004","unstructured":"Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70(2):114\u20139 (discussion 9-20).","journal-title":"Am Surg."},{"issue":"6","key":"1074_CR96","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00268-012-1560-x","volume":"36","author":"M Goldfarb","year":"2012","unstructured":"Goldfarb M, Gondek SS, Lim SM, Farra JC, Nose V, Lew JI. Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. World J Surg. 2012;36(6):1314\u20139. https:\/\/doi.org\/10.1007\/s00268-012-1560-x .","journal-title":"World J Surg"},{"issue":"1","key":"1074_CR97","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-016-0421-5","volume":"18","author":"LY Ho","year":"2017","unstructured":"Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12. https:\/\/doi.org\/10.1186\/s12882-016-0421-5 .","journal-title":"BMC Nephrol."},{"issue":"2","key":"1074_CR98","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfl583","volume":"22","author":"A Schwarz","year":"2007","unstructured":"Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007;22(2):584\u201391. https:\/\/doi.org\/10.1093\/ndt\/gfl583 .","journal-title":"Nephrol Dial Transplant."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:25:58Z","timestamp":1694651158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01074-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"27 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Author RDS is a site investigator for multicenter trials with Shire and Astellas, and has received grant support from Veloxis, Novartis, Merck. RDS has served on speaker bureaus for Veloxis and Alexion, received royalties from UpToDate. RDS\u2019s family member has stock in Pfizer. Author DC is the site principal investigator for multicenter trials with Janssen, Fibrogen, GSK, Medibeacon, and Astra Zeneca. DC receives consulting fees from Fresenius, Vifor, Medibeacon, GSK and Reata. DC has participated in review activities for Aspire Bariatrics and participated in lectures\/speaker bureaus for Fresenius Medical Care-Renal Therapies Group. Author AR and Author TTM declare that they have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}